Moneycontrol PRO
you are here: HomeNewsIndia

COVID-19 vaccine | Russia, Kerala government discuss Sputnik V manufacturing facility: Report

Sputnik V COVID-19 vaccine: In India, the RDIF has signed manufacturing partnerships with domestic firms such as Serum Institute of India, Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen

July 22, 2021 / 08:50 AM IST
Outside Russia, Sputnik V is currently manufactured at plants in South
Korea, Brazil, China, Saudi Arabia and Turkey.

Outside Russia, Sputnik V is currently manufactured at plants in South Korea, Brazil, China, Saudi Arabia and Turkey.


Russian authorities are in talks with the Kerala government for land to set up a facility to manufacture the Sputnik V COVID-19 vaccine.

"Talks are on between the Russian government and Kerala regarding the

setting up of a manufacturing unit of Sputnik V in our state," Kerala Industries Minister P Rajeev told the Business Standard.

The state government may consider areas around Thonnakkal, in

Thiruvananthapuram district, for the facility, the report said.

"Kerala State Industrial Development Corporation (KSIDC) is spearheading the talks. The initial plan is to submit a letter of intent, and KSIDC is preparing a draft," Rajeev said.

Read | Sputnik V soft launched in over 50 cities in India: Dr Reddy's

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The Russian Direct Investment Fund (RDIF), which markets the COVID-19 vaccine, had not commented on the matter when contacted by the newspaper.

Outside Russia, Sputnik V is currently manufactured at plants in South

Korea, Brazil, China, Saudi Arabia and Turkey.

Also read | 188 crore COVID vaccine doses required to inoculate 18-plus population: Govt

In India, the RDIF has formed manufacturing partnerships with domestic firms such as Serum Institute of India (SII), Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen.

The Indian government recently told Parliament that 188 crore doses are required to inoculate the entire adult population, which is projected at 94 crore. This number would reduce if single-dose jabs are approved.

Follow Moneycontrol’s full coverage of the coronavirus pandemic here
Moneycontrol News
first published: Jul 22, 2021 08:50 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark